Oncology Trials

Research & Education > TriHealth Hatton Research Institute
oncology trials

The TriHealth Hatton Research Institute's Oncology research team, and researchers at  TriHealth’s Cancer Institute and Mary Jo Cropper Family Center for Breast Care conduct important clinical trials targeting improvements in the prevention and treatment of specific kinds of cancer. Composed of a team of research nurses and clinical research assistants, the TriHealth Hatton Research Institute's Oncology research team has many decades of experience in oncology research.

Clinical trials supported by our Oncology research team include cooperative group trials sponsored by the National Cancer Institute, studies through the Catholic Health Initiative, and Pharmaceutical Trials. 

Selected trials:

What is a Clinical Trial?

A clinical trial (also called “clinical research,” “research study,” and “protocol”) is a research study that evaluates a new test, drug or treatment in people to make sure it is safe and effective. Carefully conducted clinical trials are vital to discovering new, better, safer treatments for people, and improve health and quality of life.

Clinical trials are important today for many reasons, including:

  • Contributing to improved scientific knowledge about cancer: how to detect it, and how to treat it, and even how to prevent it
  • Possibly benefiting individual patients by providing newer and better treatments, and possibly, a cure 

More Information

For additional basic information about clinical trials:

Clinical Oncology Trials

Oncology: Breast

A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3, N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy. Learn more.

Principal Investigator and Contact information:
Anne Kuritzky, MD
513 853 1300

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
Pam_Daniel@trihealth.com

A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib. Learn more.

Principal Investigator and Contact information:
Amie Jackson, MD
513 853 1300

Study Coordinator and Contact information:
Patrick Newbury, BS, CCRC
513 865 5249
Patrick_Newbury@trihealth.com

D3614C00001: A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC). Learn more.

Principal Investigator and Contact information:
Apruva Mehta, MD
513 853 1300

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
Pam_Daniel@trihealth.com

EA1181: (CompassHER2-pCR): Preoperative THP and postoperative de-escalation in patients who achieve a pathologic complete response Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to escalate or de-escalate therapy in HER2-positive breast cancer). Learn more.

Principal Investigator and Contact information:
Amie Jackson, MD
513 853 1300

Study Coordinator and Contact information:
Patrick Newbury, BS, CCRC
513 865 5249
Patrick_Newbury@trihealth.com

FLEX: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles.  Learn more.

Principal Investigator and Contact information:
Apurva Mehta, MD
513 853 1300

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
Pam_Daniel@TriHealth.com

NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer. Learn more.

Principal Investigator and Contact information:
Amie Jackson, MD
513 853 1300

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
Pam_Daniel@TriHealth.com

S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer. Learn more.

Principal Investigator and Contact information:
Amie Jackson, MD
513 853 1300

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
Pam_Daniel@TriHealth.com

Oncology: Gastrointestinal

A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair. Learn more.

Principal Investigator and Contact information:
David Draper, MD
513 853 1300

Study Coordinator and Contact information:
Patrick Newbury, BS, CCRC
513 865 5249
Patrick_Newbury@trihealth.com

EA2187: A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma. Learn More.

Principal Investigator and Contact information:
Ben Kuritzky, MD
513 853 1300

Study Coordinator and Contact information:
Patrick Newbury, BS, CCRC
513 865 5249
Patrick_Newbury@trihealth.com

Oncology: Genitourinary

A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE] Learn more.

Principal Investigator and Contact information:
Kirubel Tefera, MD
513 853 1300

Study Coordinator and Contact information:
Patrick Newbury, BS, CCRC
513 865 5249
Patrick_Newbury@trihealth.com

Oncology: Gynecology

GOG-0263: Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy Learn more.

Principal Investigator and Contact information:
Robert Neff, MD
513 853 1300

Study Coordinator and Contact information:
Diann Fischesser, BSN, RN
513 862 1892
Diann_Fischesser@trihealth.com

LCCC 1326: Metformin with the Levonorgestrel-Releasing Intrauterine Device for the treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients. Learn more.

Principal Investigator and Contact information:
Kevin Schuler, MD
513 853 1300

Study Coordinator and Contact information:
Diann Fischesser, RN
513 862 1892
Diann_Fischesser@trihealth.com

NRG-CC008: A Non-randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1. Learn More.

Principal Investigator and Contact information:
Robert Neff, MD
513 853 1300

Study Coordinator and Contact information:
Diann Fischesser, BSN, RN
513 862 1892
Diann_Fischesser@trihealth.com

NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer Learn more.

Principal Investigator and Contact information:
James Pavelka, MD
513 853 1300

Study Coordinator and Contact information:
Diann Fischesser, BSN, RN
513 862 1892
Diann_Fischesser@trihealth.com

NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer. Learn more.

Principal Investigator and Contact information:
James Pavelka, MD
513 853 1300

Study Coordinator and Contact information:
Diann Fischesser, BSN, RN
513 862 1892
Diann_Fischesser@trihealth.com

NRG-GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Learn more.

Principal Investigator and Contact information:
Robert Neff, MD
513 853 1300

Study Coordinator and Contact information:
Diann Fischesser, BSN, RN
513 862 1892
Diann_Fischesser@trihealth.com

NRG-GY020: A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer Learn more.

Principal Investigator and Contact information:
Robert Neff, MD
513 853 1300

Study Coordinator and Contact information:
Diann Fischesser, BSN, RN
513 862 1892
Diann_Fischesser@trihealth.com

Oncology: Hematology

TAK-981-1503: A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma Learn more.

Principal Investigator and Contact information:
Saulius Girnius, MD
513 853 1300

Study Coordinator and Contact information:
Melinda O’Connor, RN
513 862 4099
Melinda_O’Connor@trihealth.com

Oncology: Lung Cancer

61186372NSC3002: A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2) Learn more.

Principal Investigator and Contact information:
Andrew Parchman, MD
513 853 1300

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
Pam_Daniel@trihealth.com

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST): A screening trial for A081105 and E4512. Learn more.

Principal Investigator and Contact information:
Andrew Parchman, MD
513 853 1300

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
Pam_Daniel@trihealth.com

CA209-73L: A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC) Learn more.

Principal Investigator and Contact information:
Andrew Parchman, MD
513 853 1300

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
Pam_Daniel@trihealth.com

CA209-77T: A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer. Learn More.

Principal Investigator and Contact information:
Andrew Parchman, MD
513 853 1300

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
Pam_Daniel@trihealth.com

E4512: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations. An ALCHEMIST Treatment Trial. Learn more.  

Principal Investigator and Contact information: 
Andrew Parchman, MD
513 853 1300

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
Pam_Daniel@trihealth.com

LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study). Learn more.

Principal Investigator and Contact information:
Andrew Parchman, MD
513 853 1300

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
Pam_Daniel@trihealth.com

MK7902-008: A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (LEAP-008). Learn more.

Principal Investigator and Contact information:
Andrew Parchman, MD
513 853 1300

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
Pam_Daniel@trihealth.com

Oncology: Melanoma/Skin

20130193: A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® (Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers; and Long-term Safety in Treated Patients. Learn more.

Principal Investigator and Contact information:
Erik Dunki-Jacobs, MD
513 853 1300

Study Coordinator and Contact information:
Melinda O’Connor, RN
513 862 4099
Melinda_O’Connor@trihealth.com

Oncology: Molecular Profiling

EAY131: Molecular Analysis for Therapy Choice (MATCH).
Learn more.

Principal Investigator and Contact information:
Andrew Parchman, MD
513 853 1300

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
Pam_Daniel@trihealth.com

Diann Fischesser, RN
513 862 1892
Diann_Fischesser@trihealth.com

S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors.
Learn more.

Principal Investigator and Contact information:
Jack Basil, MD
513 853 1300

Study Coordinator and Contact information:
Diann Fischesser, RN
513 862 1892
Diann_Fischesser@trihealth.com

Oncology: Sarcoma
Oncology: Other
Oncology: Tempus TIME Trials

TPX-0005-01: A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) Learn more.

Principal Investigator and Contact information:
Faisal Adhami, MD
513 853 1300

Study Coordinator and Contact information:
Patrick Newbury, BS, CCRC
513 865 5249
Patrick_Newbury@trihealth.com

We are physicians, hospitals and communities working together to help you live better.